Apimeds Pharmaceuticals US completes merger with MindWave Innovations, issues 90.9% equity to MindWave holders

Apimeds Pharmaceuticals US, Inc.

On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.
MindWave stockholders received 29.9% of Apimeds common stock and 61% convertible preferred (as-converted), totaling 90.9% of post-merger equity.
Apimeds entered a $120.9M convertible note financing with 8% OID, issuing senior convertible notes.
CEO Erik Emerson resigned, replaced by Dr. Vin Menon; two new directors appointed.
Apimeds will effect a 1-for-10 reverse stock split and increase equity plan shares to 2,096,679.

item 1.01 item 2.01 item 2.03 item 3.02 item 5.01 item 5.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Apimeds Pharmaceuticals US, Inc. issued 712,880 shares of Acquiror Common Stock of warrant to E.F. Hutton & Co. LLC for Underwriting/placement agent services.

Security: warrant
Shares: 712,880 shares of Acquiror Common Stock
Purchaser: E.F. Hutton & Co. LLC
Consideration: Underwriting/placement agent services

Exact text from the filing

On December 1, 2025, the Acquiror issued a warrant to E.F. Hutton & Co. LLC, to purchase 712,880 shares of Acquiror Common Stock

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Apimeds Pharmaceuticals US, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-117173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.